Hubei Jumpcan Pharmaceutical's (SHSE:600566) Three-year Earnings Growth Trails the 31% YoY Shareholder Returns
Hubei Jumpcan Pharmaceutical's (SHSE:600566) Three-year Earnings Growth Trails the 31% YoY Shareholder Returns
Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) shareholders might be concerned after seeing the share price drop 22% in the last quarter. But in three years the returns have been great. In three years the stock price has launched 106% higher: a great result. So the recent fall in the share price should be viewed in that context. The thing to consider is whether the underlying business is doing well enough to support the current price.
濟川藥業(SHSE:600566)股東們紛紛表示擔憂,因爲股價在上季度急跌22%。但在三年內的回報表現非常不錯。在三年的時間裏,股價已經增長了106%:這是一個非常好的結果。因此,應該從這個角度看待最近股價的下跌。需要考慮的是,底層業務是否足夠強大,能夠支撐目前的股價。
Since the stock has added CN¥1.4b to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.
由於該股在過去一個星期內市值增加了人民幣14億,讓我們看看背後的業務績效是否推動了長期回報。
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
禾倫·巴菲特在他的論文《格雷厄姆-道德斯維爾的超級投資者》中描述了股票價格並不總是合理地反映企業的價值。通過比較每股收益(EPS)和股價隨時間變化的變化,我們可以了解到投資者對某家公司的態度如何隨時間而變化。
During three years of share price growth, Hubei Jumpcan Pharmaceutical achieved compound earnings per share growth of 30% per year. We note that the 27% yearly (average) share price gain isn't too far from the EPS growth rate. Coincidence? Probably not. That suggests that the market sentiment around the company hasn't changed much over that time. Au contraire, the share price change has arguably mimicked the EPS growth.
在三年的股價增長期間,濟川藥業實現了每股收益的複合增長率爲30%。我們注意到,27%的平均每年股價增長率與EPS增長率相差不遠。這是巧合嗎?可能不是。這表明公司周圍的市場情緒在那段時間裏沒有發生太大變化。相反,股價變化可以說模仿了EPS增長。
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
您可以在下面的圖片中查看每股收益如何隨時間變化(單擊圖表以查看確切的價值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240807/0-b7ffe66ef52f830e1ec11c5522ae7fd0-0-7249fc33287e4deb4ddb43b4fc93c75c.png/big)
It is of course excellent to see how Hubei Jumpcan Pharmaceutical has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
當然,看到濟川藥業多年來盈利增長是非常不錯的,但對於股東來說,未來更爲重要。非常值得一看的是我們免費報告,了解其財務狀況如何隨時間變化。
What About Dividends?
那麼分紅怎麼樣呢?
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Hubei Jumpcan Pharmaceutical the TSR over the last 3 years was 127%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.
除了衡量股價回報之外,投資者還應考慮總股東回報(TSR)。TSR包括任何剝離或折價融資的價值以及任何紅利,基於紅利再投資的假設。因此,對於支付豐厚紅利的公司,TSR往往比股價回報高得多。我們注意到濟川藥業在過去的3年中的TSR爲127%,比上述股價回報要好。公司支付的紅利增加了總股東回報。
A Different Perspective
不同的觀點
We're pleased to report that Hubei Jumpcan Pharmaceutical shareholders have received a total shareholder return of 34% over one year. And that does include the dividend. That's better than the annualised return of 7% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Hubei Jumpcan Pharmaceutical you should know about.
我們很高興地報告,濟川藥業股東在一年內獲得了34%的總股東回報。這已經包括了股息。這比過去半個十年每年的7%的年化回報好,表明公司最近的表現更好。在最好的情況下,這可能暗示了一些真正的業務動能,這意味着現在深入研究可能是一個好時機。雖然考慮市場條件可能對股價產生的不同影響是值得的,但還有其他更重要的因素。需要考慮風險等方面。每家公司都有風險,我們已經發現對於濟川藥業,您應該知道的風險有1個警告標誌。
Of course Hubei Jumpcan Pharmaceutical may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
當然,濟川藥業可能不是最好的股票購買選擇。因此,您可能希望查看這個免費的成長股票收集。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。